ASX:RCE

Recce Pharmaceuticals Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume630,087 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive RCE News and Ratings via Email

Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Investing in Recce Pharmaceuticals (ASX:RCE) three years ago would have delivered you a 446% gain
September 20, 2021 | finance.yahoo.com

Recce Pharmaceuticals Ltd.
August 8, 2021 | barrons.com

Recce (ASX:RCE) share price edges higher after patent approval
July 22, 2021 | msn.com

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives
July 22, 2021 | finance.yahoo.com

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives
July 21, 2021 | finance.yahoo.com

Why the Recce (ASX:RCE) share price is racing 5% higher today
July 20, 2021 | msn.com

Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria
July 20, 2021 | finance.yahoo.com

What Is The Ownership Structure Like For Recce Pharmaceuticals Ltd (ASX:RCE)?
July 19, 2021 | finance.yahoo.com

Recce Pharmaceuticals’ R327 demonstrates positive efficacy against ‘flesh-eating’ bacteria
July 19, 2021 | proactiveinvestors.com.au

Recce Pharmaceuticals Announces Multiple Patients Dosed with RECCE® 327 in Topical Phase I/II Clinical Trial for the Treatment of Infected Burn Wounds
July 12, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:RCE
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.recce.com.au
Phone: 61 2 8075 4585
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $1.64 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 13.57
Book Value: A$0.12 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 19.64
Quick Ratio: 19.59

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.91 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Recce Pharmaceuticals.

4.5 Community Rank

Outperform Votes
Recce Pharmaceuticals has received 19 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Recce Pharmaceuticals has received 9 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Recce Pharmaceuticals has received 67.86% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Recce Pharmaceuticals and other stocks. Vote “Outperform” if you believe RCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Recce Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Recce Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Recce Pharmaceuticals insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

What stocks does MarketBeat like better than Recce Pharmaceuticals?: Wall Street analysts have given Recce Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Recce Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
How were Recce Pharmaceuticals' earnings last quarter?: Recce Pharmaceuticals Ltd (ASX:RCE) issued its earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter.
View Recce Pharmaceuticals' earnings history.
Who are Recce Pharmaceuticals' key executives?: Recce Pharmaceuticals' management team includes the following people:
Mr. James Hamilton-Bray Graham, CEO & MD
Ms. Michele Keryn Dilizia, Chief Scientific Director & Exec. Director
Dr. Justin Ward, Principal Quality Chemist & Exec. Director
Mr. Arthur Kollaras, Principal Engineer & Head of Manufacturing
Mr. Justin Reynolds, Chief Financial Officer
Mr. Daniel Astudillo B.A., B.Com., M.B.A., Marketing Mang.
Prof. Philip Sutton, Member of Clinical Advisory Committee & Head of Helicobacter Pylori Devel. Program
Mr. Alistair McKeough BA, LLB, LLM, Company Sec.
Who are some of Recce Pharmaceuticals' key competitors?: Some companies that are related to Recce Pharmaceuticals include Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group (MYX), Medical Developments International (MVP), Opthea (OPT), Otsuka (OTSKY), Patrys (PAB), Pharmaxis (PXS), Roche (RHHVF), Sanofi (SNYNF), Sanofi (SAN), Sinclair Pharma (SPH) and Vita Life Sciences (VLS).
View all of RCE's competitors.
What other stocks do shareholders of Recce Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Immutep (IMMP), Mavenir (MVNR), Applied Optoelectronics (AAOI), 5G Networks (5GN), Ilika (IKA), IOOF (IFL), Turtle Beach (HEAR) and First Graphene (FGR).
What is Recce Pharmaceuticals' stock symbol?: Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE."
How much money does Recce Pharmaceuticals make?: Recce Pharmaceuticals has a market capitalization of $0.00 and generates $1.64 million in revenue each year.
What is Recce Pharmaceuticals' official website?: The official website for Recce Pharmaceuticals is www.recce.com.au.
How can I contact Recce Pharmaceuticals?: The company can be reached via phone at 61 2 8075 4585.

This page was last updated on 9/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.